安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ImmunoGen Announces Pricing of Public Offering of Common Stock
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology
- Boehringer Ingelheim and ImmunoGen Sign Exclusive License Agreement
ImmunoGen, Inc develops innovative biopharmaceuticals, primarily for cancer treatment The Company has created potent tumor-activated prodrugs, consisting of drugs coupled to monoclonal antibodies, for delivery to and destruction of cancer cells
- SEC Filing | ImmunoGen, Inc.
2 Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc [ IMGN ] 5 Relationship of Reporting Person (s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)
- First Clinical Data Presented with IMGN853, ImmunoGen, Inc. s Potential . . .
WALTHAM, Mass --(BUSINESS WIRE)-- ImmunoGen, Inc (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate
- ImmunoGen Reports Financial Results for Quarter Ended September 30 and . . .
"During the last quarter, we strengthened our business and better positioned ImmunoGen for long-term growth," said Mark Enyedy, president and chief executive officer of ImmunoGen
- ImmunoGen BioInvent Sign Antibody Manufacturing Agreement
ImmunoGen, Inc develops innovative biopharmaceuticals, primarily for cancer treatment The Company has created potent tumor-activated prodrugs (TAPs), consisting of small molecular, cytotoxic drugs coupled to monoclonal antibodies, for delivery to and destruction of cancer cells
- ImmunoGen, Inc. Regains Development and Commercialization Rights for . . .
ImmunoGen holds the Investigational New Drug application (IND) for cantuzumab mertansine and has rights to all clinical data generated in the Phase I studies The two companies will work together to ensure a smooth transition of all study data
- ImmunoGen, Inc. Announces Exercise of Over-allotment Option
ImmunoGen, Inc develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and linkage of potent cancer-cell killing agents (CKAs) to such antibodies
|
|
|